Northwestern China: A place to learn more on oesophageal cancer. Part two: Gene alterations and polymorphisms

European Journal of Gastroenterology and Hepatology

Volumn 23, Issue 12, 2011, Pages 1087-1099

  Zheng, Shutao ^a   Vuitton, Lucine ^c   Sheyhidin, Ilyar ^b   Vuitton, Dominique Angèle ^d   Zhang, Yueming ^a   Lu, Xiaomei ^a  

^a XINJIANG MEDICAL UNIVERSITY   (China)

^b Department of Thoracic Surgery   (China)

^c UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^d UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

China; gene alteration; Kazakh; microRNA; mitogen activated protein kinase; oesophageal cancer; polymorphism; SELDI TOF MS; Uygur; Xinjiang

Indexed keywords

CYCLIN D1; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL KINASE; PROTEIN BCL 2; PROTEIN P53; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR;

ADENOMATOUS POLYP; APOPTOSIS; CANCER GROWTH; CARCINOGENESIS; CHINA; CHROMOSOME DELETION; DNA REPAIR; EARLY DIAGNOSIS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENE EXPRESSION; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HETEROZYGOSITY LOSS; HIGH RISK POPULATION; HUMAN; MOLECULAR BIOLOGY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEOMICS; REVIEW; RISK FACTOR; XENOBIOTIC METABOLISM;

CARCINOMA, SQUAMOUS CELL; CHINA; CHROMOSOME DELETION; ESOPHAGEAL NEOPLASMS; GENES, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LOSS OF HETEROZYGOSITY; POLYMORPHISM, GENETIC;

EID: 80955167005     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32834a14d9     Document Type: Review

References (98)

1. Zheng S, Vuitton L, Sheyhidin I, Vuitton DA, Zhang Y, Lu X. Northwestern China: a place to learn more on oesophageal cancer. Part one: behavioural and environmental risk factors. Eur J Gastroenterol Hepatol 2010; 22: 917-925.
2. Koppert LB, Wijnhoven BPL, Dekken HV, Tilanus HW, Dinjens WNM. The molecular biology of esophageal adenocarcinoma. J Surg Oncol 2005; 92:169-190. (Pubitemid 41779299)
3. Hu N, Clifford RJ, Yang HH, Wang C, Goldstein AM, Ding T, et al. Genome wide analysis of DNA copy number neutral loss of heterozygosity (CNNLOH) and its relation to gene expression in esophageal squamous cell carcinoma. BMC Genomics 2010; 11:576.
4. Saeki H, Kitao H, Yoshinaga K, Nakanoko T, Kubo N, Kakeji Y, et al. Copy-neutral loss of heterozygosity at the p53 locus in carcinogenesis of esophageal squamous cell carcinomas associated with p53 mutations. Clin Cancer Res 2011; 17:1731-1740.
5. Mori T, Yanagisawa A, Kato Y, Miura K, Nishihira T, Mori S, et al. Accumulation of genetic alterations during esophageal carcinogenesis. Hum Mol Genet 1994; 3:1969-1971. (Pubitemid 24341373)
6. Ogasawara S, Maesawa C, Tamura G, Satodate R. Frequent microsatellite alterations on chromosome 3p in esophageal squamous cell carcinoma. Cancer Res 1995; 55:891-894.
7. Qin YR, Fu L, Sham PC, Kwong DL, Zhu CL, Chu KK, et al. Single nucleotide polymorphism-mass array reveals commonly deleted regions at 3p22 and 3p14.2 associate with poor clinical outcome in esophageal squamous cell carcinoma. Int J Cancer 2008; 4:826-830. (Pubitemid 352032408)
8. Huang XP, Fang W, Liu XY, Xu X, Hu H, Chen BS, et al. Allelic loss on 13q in oesophageal squamous cell carcinomas from northern China. Cancer Lett 2002; 185:87-94. (Pubitemid 34876537)
9. Zhao XX, Wang LR, Shen WZ, Ou YJ, Wu MB, Zhang Z. Loss of heterozygocity at chromosomes 3p24 allelic in the Kazakh patients with esophageal cancer. Acta Academiae Medicinae Sinicae 1996; 19:143-145.
10. Chen J, Wang BY, Baikeli. S, Tang NH, Sheng WZ, Wu GZ, et al. Putative tumor suppressor genes on chromosome 3p24 and 11p15.5 in esophageal carcinoma. J Xinjiang Med Univ 2000; 23:213-215.
11. Li T, Wu MB, Zhao XX, Zhang Z, Wu GZ, Xiahding Y, et al. Loss of heterozygosity and cloning of human chromosome 3p24 in oesophageal carcinoma. J Xinjiang Med Univ 2003; 26:224-226.
12. Abudujilili G. Specific LOH of chromosome of esophageal carcinoma of Kazakh Nationality. Chin J Compr Clin Hyg 2005; 7:729-731.
13. Zhu C, Qin YR, Xie D, Chua DT, Fung JM, Chen L, et al. Characterization of tumor suppressive function of P300/CBP-associated factor at frequently deleted region 3p24 in esophageal squamous cell carcinoma. Oncogene 2009; 28:2821-2828.
14. Pons D, Trompet S, de Craen AJ, Thijssen PE, Quax PH, de Vries MR, et al. Genetic variation in PCAF, a key mediator in epigenetics, is associated with reduced vascular morbidity and mortality: evidence for a new concept from three independent prospective studies. Heart 2011; 97:143-150.
15. Sun S, Zhang X, Zhang Y, Wang H, Yu Y, Zhang M. Bioinformatic system modeling on hetian uygur natural longevity people. Conf Proc IEEE Eng Med Biol Soc 2005; 1:813-816. (Pubitemid 46228990)
16. Li NF, Zhang JH, Yang J, Zhou L, Luo WL, Guo YY, et al. Association of genetic variations of regulator of G-protein signaling 2 with hypertention in the general Xinjiang Kazakh population. Clin Exp Hypertens 2010; 32:256-261.
17. Kinzler KW, Nilbert MC, Vogelstein B, Bryan TM, Levy DB, Smith KJ, et al. Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science 1991; 251:1366-1370. (Pubitemid 21916922)
18. Yunusi K, Wang LR, Zhao XX, Baikeli S, Wu GZ, Awati Y, et al. Study on the loss of heterozygocity and point mutation of APC tumor supressor gene in Xinjiang Kazakh's esophageal cancer. J Xinjiang Med Univ 1999; 22:79-81.
19. Li HC, Lu SH. Mutation of tumor suppressor genes APC and MCC in human esophageal cancer. Chin J Oncol 1995; 17:9-12.
20. Lu SH. Alterations of oncogenes and tumor suppressor genes in oesophageal cancer in China. Mutat Res 2000; 462:343-353. (Pubitemid 30190240)
21. Sarbia M, Geddert H, Klump B, Kiel S, Iskender E, Gabbert HE. Hypermethylation of tumor suppressor genes (p16INK4A, p14ARF and APC) in adenocarcinomas of the upper gastrointestinal tract. Int J Cancer 2004; 111:224-228. (Pubitemid 38924699)
22. Kim YT, Park JY, Jeon YK, Park SJ, Song JY, Kang CH, et al. Aberrant promoter CpG island hypermethylation of the adenomatosis polyposis coli gene can serve as a good prognostic factor by affecting lymph node metastasis in squamous cell carcinoma of the esophagus. Dis Esophagus 2009; 22:143-150.
23. Zare M, Jazii FR, Alivand MR, Nasseri NK, Malekzadeh R, Yazdanbod M. Qualitative analysis of Adenomatous Polyposis Coli promoter: hypermethylation, engagement and effects on survival of patients with esophageal cancer in a high risk region of the world, a potential molecular marker. BMC Cancer 2009; 9:24.
24. Hoffmann AC, Vallböhmer D, Prenzel K, Metzger R, Heitmann M, Neiss S, et al. Methylated DAPK and APC promoter DNA detection in peripheral blood is significantly associated with apparent residual tumor and outcome. J Cancer Res Clin Oncol 2009; 135:1231-1237.
25. Kaifi JT, Rawnaq T, Schurr PG, Yekebas EF, Mann O, Merkert P, et al. Short tandem repeat polymorphism in exon 4 of esophageal cancer-related gene 2 detected in genomic DNA is a prognostic marker for esophageal cancer. Am J Surg 2007; 194:380-384. (Pubitemid 47212041)
26. Cheng X, Lu SH, Cui Y. ECRG2 regulates ECM degradation and uPAR/FPRL1 pathway contributing cell invasion/migration. Cancer Lett 2010; 290:87-95.
27. Yue CM, Bi MX, Tan W, Deng DJ, Zhang XY, Guo LP, et al. Short tandem repeat polymorphism in a novel esophageal cancer-related gene (ECRG2) implicates susceptibility to esophageal cancer in Chinese population. Int J Cancer 2004; 108:232-236. (Pubitemid 37541776)
28. Chen XC, Pang LJ, Chen L, Yang L, Zhang JF, Qi Y, et al. Relationship between polymorphism esophageal cancer related gene 2 and esophageal squamous cell cancer in Han and Kazakh populations in Xinjiang Uygur Autonomous Region. World Chin J Digestol 2007; 15:2408-2412. (Pubitemid 350082879)
29. Jain M, Kumar S, Ghoshal UC, Mittal B. Association of ECRG2 TCA short tandem repeat polymorphism with the risk of oesophageal cancer in a North Indian population. Clin Exp Med 2008; 8:73-78. (Pubitemid 351999725)
30. González-Mariscal L, Tapia R, Chamorro D. Crosstalk of tight junction components with signaling pathways. Biochim Biophys Acta 2008; 1778:729-756. (Pubitemid 351317800)
31. Jiang W, Kahn SM, Tomita N, Zhang YJ, Lu SH, Weinstein IB. Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Res 1992; 52:2980-2983.
32. Wang LD, Shi ST, Zhou Q, Goldstein S, Hong JY, Shao P, et al. Changes in p53 and cyclin D1 protein levels and cell proliferation in different stages of human esophageal and gastric-cardia carcinogenesis. Int J Cancer 1994; 59:514-519. (Pubitemid 24357277)
33. Gramlich TL, Fritsch CR, Maurer D, Eberle M, Gansler TS. Differential polymerase chain reaction assay of cyclin D1 gene amplification in esophageal carcinoma. Diagn Mol Pathol 1994; 3:255-259. (Pubitemid 24378940)
34. Takamura H, Fushida S, Hashimoto T, Yagi M, Miyazaki I. Analysis of the p16INK4, p15INK4B genes abnormality and the amplification of cyclin D1 gene in esophageal cancer. Nippon Rinsho 1996; 54:1043-1048.
35. Sarbia M, Stahl M, Fink U, Heep H, Dutkowski P, Willers R, et al. Prognostic significance of cyclin D1 in esophageal squamous cell carcinoma patients treated with surgery alone or combined therapy modalities. Int J Cancer 1999; 84:86-91. (Pubitemid 29059114)
36. Yang ZJ, Feng N, Gao SL. Expression and Clinic significance of Rb, CyclinD1 gene in Kazakh's esophageal cancer. Chin Mag Clin Med Prof Res 2004; 124:13123-13124.
37. Lam AK. Molecular biology of esophageal squamous cell carcinoma. Crit Rev Oncol Hematol 2000; 33:71-90. (Pubitemid 30085471)
38. Huang XP, Rong TH, Lin P, Wu QL, Yao GY, Hou JH, et al. Cyclin D1 overexpression in oesophageal cancer from southern China and its clinical significance. Cancer Lett 2006; 231:94-101.
39. Chan WC, Tang CM, Lau KW, Lung ML. P16 tumor suppressor gene mutation in Chinese esophageal carcinomas in HongKong. Cancer Lett 1997; 115:201-206. (Pubitemid 27196606)
40. Gameildien W, Victor TC, Mugwanya D, Stepien A, Gelderblom WCA, Marasas WF, et al. p53 and p16 CDKN2 gene mutations in esophageal tumors from a high-incidence area in South Africa. Int J Cancer 1998; 78:544-549. (Pubitemid 28507175)
41. Jin SQ, Peng Q, Lu SH, Cheng RH, Zhou JX, Su T. Deletions of MTS1/p16 gene in human esophageal carcinoma. Chin J Oncol 1998; 20:9-11.
42. Yunusi K, Wang LR, Baikeli S, Zhao XX, Wu GZ, Awati Y, et al. Study on the homozygous deletion and expression of the tumor suppressor gene p16 in Xinjiang Kazakh's oesophageal cancer. J Xinjiang Med Univ 2000; 23:10-12.
43. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 8:917-921. (Pubitemid 27353455)
44. Li H, Lu XM, Zhao XX, Xu SY, Pang ZL, Chen Y, et al. Expression and significance of Survivin and Cyclin D1 gene in Kazakh's esophageal cancer. J Xinjiang Med Univ 2007; 30:560-562.
45. Yang ZJ. The investigation about the clinic significance and expression of Fas, Bax in Kazakh and Han oesophageal cancer tissue. Chin Mag Clin Med Prof Res 2004; 128:13590-13593.
46. Kuwano H, Kato H, Miyazaki T, Fukuchi M, Masuda N, Nakajima M, et al. Genetic alterations in esophageal cancer. Surg Today 2005; 35:7-18. (Pubitemid 40941123)
47. Pantelis A, Pantelis D, Ruemmele P, Hartmann A, Hofstaedter F, Buettner R, et al. p53 Codon 72 polymorphism, loss of heterozygosity and high-risk human papillomavirus infection in a low-incidence German esophageal squamous cell carcinoma patient cohort. Oncol Rep 2007; 17: 1243-1248.
48. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63:1129-1136. (Pubitemid 120035062)
49. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998; 393:229-234. (Pubitemid 28261713)
50. He BC, Duan GC, Cai Lin. Study on relationship between high risk HPV infection and p53 polymorphisms and oesophagea cancer. Strait J Prev Med 2007; 13:8-10.
51. He BC, Duan GC, Zhang WD, Dai M, Xie J, Xi YL. Study on p53 codon 72 polymorphism and human papillomavirus-associated oesophagea cancer in AnYang area, Henan province. Chin J Gastro Hepa 2005; 14:374-376.
52. Chen CL, Wu MB, Zhang LW. Abnormal expression of p53, p16 and Rb proteins in oesophageal cancer from different nationalities in Xinjiang and its significance. Tumor 2002; 22:411-414.
53. Hayes VM, Hofstra RM, Buys CH, Hollema H, van der Zee AG. Homozygous arginine-72 in wild type p53 and risk of cervical cancer. Lancet 1998; 352:1756. (Pubitemid 28534966)
54. Humbey O, Aubin F, Cairey-Remonnay S, Riethmuller D, Pretet JL, Fest T, et al. TP53 polymorphism at exon 4 in caucasian women from eastern France: lack of correlation with HPV status and grade of cervical precancerous lesions. Eur J Obstet Gynecol Reprod Biol 2002; 103:60-64. (Pubitemid 34606957)
55. Cairey-Remonnay S, Guérrini JS, Algros MP, Mougin C, Bittard H, Aubin F. Detection of the human papillomavirus and analysis of the TP53 polymorphism of exon 4 at codon 72 in penile squamous cell carcinomas. Eur J Cancer 2003; 39:684-690. (Pubitemid 36287382)
56. Nimura Y, Yokoyama S, Fujimori M, Aoki T, Adachi W, Nasu T, et al. Genotyping of the CYP1A1 and GSTM1 genes in esophageal carcinoma patients with special reference to smoking. Cancer 1997; 80:852-857. (Pubitemid 27360465)
57. Lu XM, Zhang YM, Lin RY, Arzi G, Wang X, Zhang YL, et al. Relationship between genetic polymorphisms of metabolizing enzymes CYP2E1, GSTM1 and Kazakh's esophageal squamous cell cancer in Xinjiang, China. World J Gastroenterol 2005; 11:3651-3654. (Pubitemid 41149257)
58. Wang XM, Zhang WQ, Chen B, He L, Alimutai, Hanati, et al. Study on C667T gene polymorphism and susceptibility to esophageal cancer in Kazakhs. Chin J Public Health 2007; 23:937-938.
59. Tan W, Song N, Wang GQ, Liu Q, Tang HJ, Kadlubar FF, et al. Impact of genetic polymorphisms in cytochrome P450 2E1 and glutathione S-transferases M1, T1, and P1 on susceptibility to esophageal cancer among high-risk individuals in China. Cancer Epidemiol Biomarkers Prev 2000; 9:551-556. (Pubitemid 30396175)
60. Li D, Dandara C, Parker MI. Association of cytochrome P450 2E1 genetic polymorphisms with squamous cell carcinoma of the oesophagus. Clin Chem Lab Med 2005; 43:370-375. (Pubitemid 41460641)
61. Chelule PK, Pegoraro RJ, Gqaleni N, Dutton MF. The frequency of cytochrome P450 2E1 polymorphisms in Black South Africans. Dis Markers 2006; 22:351-354. (Pubitemid 46333634)
62. Malik MA, Upadhyay R, Mittal RD, Zargar SA, Mittal B. Association of xenobiotic metabolizing enzymes genetic polymorphisms with esophageal cancer in Kashmir Valley and influence of environmental factors. Nutr Cancer 2010; 62:734-742.
63. Ergheim I, Wolfgarten E, Bollschweiler E, Hölscher AH, Bode C, Parlesak A. Cytochrome P450 levels are altered in patients with esophageal squamous-cell carcinoma. World J Gastroenterol 2007; 13:997-1002. (Pubitemid 46510999)
64. Lu XM, Zhang YM, Lin RY, Zhan YL, Tuerxun Azguli, Hu YB, et al. Study on relationship between glutathione S-transferase M1, T1 genotypes and Kazakh esophageal cancer. Chin J Disease Contr Prev 2003; 7:491-493.
65. Lin DX, Tang YM, Peng Q, Lu SX, Ambrosone CB, Kadlubar FF. Susceptibility to esophageal cancer and genetic polymorphisms in glutathione S-transferases T1, P1, and M1 and cytochrome P450 2E1. Cancer Epidemiol Biomarkers Prev 1997; 11:1013-1018.
66. Ma WJ, Lv GD, Zheng ST, Huang CG, Liu Q, Wang X, et al. DNA polymorphism and risk of esophageal squamous cell carcinoma in a population of North Xinjiang, China. World J Gastroenterol 2010; 16: 641-647.
67. Huang CG, Lv GD, Liu T, Liu Q, Feng JG, Lu XM. Polymorphisms of COMT and XPD and risk of esophageal squamous cell carcinoma in a population of Yili Prefecture, in Xinjiang, China. Biomarkers 2011; 16:37-41.
68. Zhang JF, Pang LJ, Jin Zhao, Chen XC, Gu LY, Ge CM, et al. Association of methylenetetrahydrofolate reductase C677T polymorphism with susceptibility to esophageal cancer in Kazakh and Han populations in Xinjiang Uygur Autonomous Region. World Chin J Digestol 2006; 14:1475-1480. (Pubitemid 44032723)
69. Zhang JF, Pang LJ, Jin Zhao, Chen XC, Gu LY, Ge CM, et al. Relationship between polymorphism of Methylenetetrahydrofolate Reductase C677T and Kazakh's esophageal squamous cell cancer in Xinjiang. J ShiHeZi Univ (Natu Sci) 2006; 24:138-141.
70. Warzocha K, Ribeiro P, Bienvenu J, Roy P, Charlot C, Rigal D, et al. Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood 1998; 91:3574-3581. (Pubitemid 28225722)
71. Zhang HY, Zhang HM, Chen L, Yang L, Li HA, Jiang JF, et al. Relationship between polymorphisms of tumor necrosis factor-alpha and Kazakh esophageal squamous cell cancer in Xinjiang. World Chin J Digestol 2007; 15:2236-2241. (Pubitemid 47425046)
72. Guo W, Wang N, Li Y, Zhang JH. Polymorphisms in tumor necrosis factor gene and susceptibility to oesophageal squamous cell carcinoma and gastric cardiac adenocarcinoma in a population of high incidence region of North China. Chin Med J(Engl) 2005; 118:1870-1878. (Pubitemid 41748746)
73. Kuwahara A, Yamamori M, Fujita M, Okuno T, Tamura T, Kadoyama K, et al. TNFRSF1B A1466G genotype is predictive of clinical efficacy after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. J Exp Clin Cancer Res 2010; 29:100.
74. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004; 64:3753-3756. (Pubitemid 38697282)
75. Ma WJ, Tuersun A, Liu Q, Liu H, Zheng ST, Huang CG, et al. Role of microRNA-21 and effect on PTEN in Kazakh's esophageal squamous cell carcinoma. Mol Biol Rep 2010; 38:3253-3260.
76. Matsushima K, Isomoto H, Kohno S, Nakao K. MicroRNA and esophageal squamous cell carcinoma. Digestion 2010; 82:138-144.
77. Guo H, Wang K, Xiong G, Hu H, Wang D, Xu X, et al. A functional variant in microRNA-146a is associated with risk of esophageal squamous cell carcinoma in Chinese Hans. Fam Cancer 2010; 9:599-603.
78. Ogawa R, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Katada T, et al. Expression profiling of micro-RNAs in human esophageal squamous cell carcinoma using RT-PCR. Med Mol Morphol 2009; 42:102-109.
79. Guo Y, Chen ZL, Zhang L, Zhou F, Shi SS, Feng XL, et al. Distinctive MicroRNA profiles relating to patient survival in esophageal squamous cell carcinoma. Cancer Res 2008; 68:26-33. (Pubitemid 351380102)
80. Mathé EA, Nguyen GH, Bowman ED, Zhao Y, Budhu A, Schetter AJ, et al. MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res 2009; 15:6192-6200.
81. Akagi I, Miyashita M, Ishibashi O, Mishima T, Kikuchi K, Makino H, et al. Relationship between altered expression levels of MIR21, MIR143, MIR145, and MIR205 and clinicopathologic features of esophageal squamous cell carcinoma. Dis Esophagus 2011; 24:523-530.
82. Oncozato W, Yamashita K, Yamashita K, Kuba T, Katoh H, Nakamura T, et al. Genetic alterations of K-ras may reflect prognosis in stage III colon cancer patients below 60 years of age. J Surg Oncol 2011; 103:25-33.
83. Miron A, Varadi M, Carrasco D, Li HL, Luongo L, Kim HJ, et al. PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Research 2010; 70:5674-5678.
84. Langosch KM, Bamberger AM, Rieck G, Grund D, Hemminger G, Müller V, et al. Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer. Br J Cancer 2005; 92:2206-2215. (Pubitemid 40966259)
85. Lee HJ, Kim DI, Kang GH, Kwak C, Ku JH, Moon KC. Phosphorylation of ERK1/2 and prognosis of clear cell renal cell carcinoma. Urology 2009; 73:394-399.
86. Mori R, Ishiguro H, Kimura M, Mitsui A, Sasaki H, Tomoda K, et al. PIK3CA Mutation status in Japanese esophageal squamous cell carcinoma. J Surg Res 2008; 145:320-326.
87. Zheng ST, Liu T, Tuersun A, Huo Q, Liu Q, Huang CG, et al. Expression of ERK1/2 MAPK signal transduction pathway in the esophageal cancer tissues of Kazakh patients. Zhonghua Zhong Liu Za Zhi 2011; 33:421-425.
88. Zheng ST, Huo Q, Tuerxun A, Ma WJ, Lv GD, Huang CG, et al. The expression and activation of ERK/MAPK pathway in human oesoaphgeal cancer cell line EC9706. Mol Bio Rep 2011; 38:865-872.
89. Huo Q, Zheng ST, Tuersun A, Huang CG, Liu Q, Zhang X, et al. shRNA interference for extracellular signal-regulated kinase 2 can inhibit the growth of esophageal cancer cell line Eca109. J Recept Signal Transduct Res 2010; 30:170-177.
90. Zhu X, Ding M, Yu ML, Feng MX, Tan LJ, Zhao FK. Identification of galectin-7 as a potential biomarker for esophageal squamous cell carcinoma by proteomic analysis. BMC Cancer 2010; 10:290.
91. Uemura N, Nakanishi Y, Kato H, Saito S, Nagino M, Hirohashi S, Kondo T. Transglutaminase 3 as a prognostic biomarker in esopahgeal cancer revealed by proteomics. Int J Cancer 2009; 124:2106-2115.
92. Fu L, Qin YR, Xie D, Chow HY, Ngai SM, Kwong DL, et al. Identification of alpha-actinin 4 and 67 KDa laminin receptor as stage-specific markers in esophageal cancer via proteomic approaches. Cancer 2007; 110:2672-2681. (Pubitemid 350250336)
93. Xu SY, Liu Z, Ma WJ, Sheyhidin I, Zheng ST, Lu XM. New potential biomarkers in the diagnosis of esophageal squamous cell carcinoma. Biomarkers 2009; 14:340-346.
94. Liu WL, Zhang G, Wang JY, Cao JY, Guo XZ, Xu LH, et al. Proteomics-based identification of autoantibody against CDC25B as a novel serum marker in esophageal squamous cell carcinoma. Biochem Biophys Res Commun 2008; 375:440-445.
95. Wang Y, Zhang ZS, Liu F, Mao YS, Zhang JS, Zhang DC, et al. A serum pattern for the diagnosis of esophageal squamous cell carcinoma. Chin J Lab Med 2004; 27:634-637.
96. Liu CZ, Zhu PY, Shi MX, Liu JB, Wang WJ, Liao P, et al. Screening of serum proteome biomarker of esophageal squamous cell carcinoma by WCX2 protein chip. China Oncol 2007; 17:701-705.
97. Fujita Y, Nakanishi T, Miyamoto Y, Hiramatsu M, Mabuchi H, Miyamoto A, et al. Proteomics-based identification of autoantibody against heat shock protein 70 as a diagnostic marker in esophageal squamous cell carcinoma. Cancer Lett 2008; 263:280-290.
98. Wang LD, Zhou FY, Li XM, Sun LD, Song X, Jin Y, et al. Genome-wide association study of esophageal squamous cell carcinoma in Chinese subjects identifies susceptibility loci at PLCE1 and C20orf54. Nat Genet 2010; 42:759-763.